



Ending Global HIV/AIDS

90% Diagnosis + 90% Therapy + 90% Viral Suppression



Through our Corporate Grants program, Gilead supports the efforts of community-based organizations, public health entities and similar organizations in communities with high incidence of HIV/AIDS with the aim of:

- providing HIV diagnostic services, helping 90% of people living with HIV know their status;
- helping enable access to sustained anti-retroviral therapy for 90% of people living with HIV; and
- helping secure and maintain viral suppression for 90% of people receiving therapy.

Selection Criteria

Gilead encourages proposals from organizations that can demonstrate the following:

- Ability to clearly state how "underserved" populations (individuals who are living with HIV, but are unaware of their HIV status, do not have sustainable access to therapy and/or related viral suppression) will be reached through clearly defined goals and milestones.
- A focus on cost-effective policies and interventions that support individuals requiring long-term access to HIV services and other health services, including diagnostic testing, medications and healthcare for suppressing viral load.

Eligibility

- Organizations must be classified as a not-for-profit/non-governmental-organization (NGO) and headquartered in a country where HIV transmission rates are increasing. Organizations must demonstrate a commitment to improving public health, including but not limited to providing social services, education or advocacy for "underserved" or "hard to reach" populations.

Application Process

- Beginning **August 8th, 2016** applications will be accepted on a continual basis, only through Gilead's online giving portal. Decisions are typically communicated within 12 weeks from the submission date.
- Questions about the announcement or application process should be submitted to grants@gilead.com
- Please review the grant Terms and Conditions prior to submitting an application. A sample grant application form can be found by clicking [here](#).
- Please include the phrase 90-90-90 in the project title section of the grant application.

Program Specifics

- This program is designed to support UNAIDS in its 90-90-90 treatment goal of ending the AIDS epidemic.
- Awards are for a one-year period.
- Acceptance of an application to the Corporate Grants program is not a promise of funding.
- Application is agnostic to and not dependent on use of any Gilead Sciences product.

In addition to the criteria above, proposals will be evaluated based on a number of additional factors. Gilead reserves the right to approve or disapprove any application. Award of a grant in any one year does not imply that a subsequent grant will be awarded without further application and approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.